Cancer-induced Pain Is Associated With Poor Overall Survival of Urothelial Carcinoma Patients Treated With Enfortumab Vedotin.

IF 1.8 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

In vivo Pub Date : 2025-05-01 DOI:10.21873/invivo.13953

Mamoru Hashimoto, Ken Fukiage, Kosei Taniguchi, Takafumi Minami, Takafumi Yanagisawa, Wataru Fukuokaya, Ryoichi Maenosono, Yuki Yoshikawa, Takuya Tsujino, Masanobu Saruta, Kiyoshi Takahara, Yosuke Hirasawa, Takeshi Hashimoto, Yoshio Ohno, Takahiro Kimura, Ryoichi Shiroki, Kazutoshi Fujita

{"title":"Cancer-induced Pain Is Associated With Poor Overall Survival of Urothelial Carcinoma Patients Treated With Enfortumab Vedotin.","authors":"Mamoru Hashimoto, Ken Fukiage, Kosei Taniguchi, Takafumi Minami, Takafumi Yanagisawa, Wataru Fukuokaya, Ryoichi Maenosono, Yuki Yoshikawa, Takuya Tsujino, Masanobu Saruta, Kiyoshi Takahara, Yosuke Hirasawa, Takeshi Hashimoto, Yoshio Ohno, Takahiro Kimura, Ryoichi Shiroki, Kazutoshi Fujita","doi":"10.21873/invivo.13953","DOIUrl":null,"url":null,"abstract":"Background/aim: Cancer-induced pain (CIP) exacerbates patient's quality of life. However, it is unknown whether CIP is associated with survival in urothelial carcinoma (UC) patients treated with enfortumab vedotin (EV). This study retrospectively investigated the prognostic significance of CIP in EV-treated UC patients.Patients and methods: We analyzed clinical data from patients with locally advanced or metastatic UC who received EV treatment, assessing various factors such as age, metastasis site, ECOG Performance Status (PS), and CIP status prior to treatment. CIP was determined based on clinical records cancer-related pain or the use of analgesics for pain management.Results: A total of 114 patients (78 males and 36 females) were included in the study. The group with CIP included significantly higher number of patients with bone metastasis. Progression-free survival of the patients with CIP was not significantly different from those without CIP. However, the patients with CIP showed worse overall survival (OS) than those without CIP. Cox proportional regression analysis showed that CIP, liver metastasis, and ECOG PS were significant predictors of poorer OS.Conclusion: CIP before the treatment of EV was a significant predictor of reduced OS in patients with UC. Early management of CIP or initiation of EV therapy before CIP development may improve survival outcomes.","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 3","pages":"1533-1539"},"PeriodicalIF":1.8000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12041981/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"In vivo","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/invivo.13953","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: Cancer-induced pain (CIP) exacerbates patient's quality of life. However, it is unknown whether CIP is associated with survival in urothelial carcinoma (UC) patients treated with enfortumab vedotin (EV). This study retrospectively investigated the prognostic significance of CIP in EV-treated UC patients.

Patients and methods: We analyzed clinical data from patients with locally advanced or metastatic UC who received EV treatment, assessing various factors such as age, metastasis site, ECOG Performance Status (PS), and CIP status prior to treatment. CIP was determined based on clinical records cancer-related pain or the use of analgesics for pain management.

Results: A total of 114 patients (78 males and 36 females) were included in the study. The group with CIP included significantly higher number of patients with bone metastasis. Progression-free survival of the patients with CIP was not significantly different from those without CIP. However, the patients with CIP showed worse overall survival (OS) than those without CIP. Cox proportional regression analysis showed that CIP, liver metastasis, and ECOG PS were significant predictors of poorer OS.

Conclusion: CIP before the treatment of EV was a significant predictor of reduced OS in patients with UC. Early management of CIP or initiation of EV therapy before CIP development may improve survival outcomes.

查看原文本刊更多论文

癌症引起的疼痛与使用安可通维多汀治疗的尿路上皮癌患者较差的总生存率相关。

背景/目的：癌症性疼痛（CIP）恶化了患者的生活质量。然而，目前尚不清楚CIP是否与接受安替妥单抗（EV）治疗的尿路上皮癌（UC）患者的生存率相关。本研究回顾性探讨了CIP在ev治疗UC患者中的预后意义。患者和方法：我们分析了接受EV治疗的局部晚期或转移性UC患者的临床数据，评估了治疗前的各种因素，如年龄、转移部位、ECOG表现状态（PS）和CIP状态。CIP是根据临床记录确定的癌症相关疼痛或使用镇痛药进行疼痛管理。结果：共纳入114例患者，其中男性78例，女性36例。CIP组出现骨转移的患者明显增多。CIP患者的无进展生存期与非CIP患者无显著差异。然而，CIP患者的总生存期（OS）比无CIP患者差。Cox比例回归分析显示，CIP、肝转移和ECOG PS是较差OS的显著预测因子。结论：EV治疗前CIP是UC患者OS降低的重要预测因子。早期处理CIP或在CIP发展之前开始EV治疗可能改善生存结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

In vivo 医学-医学：研究与实验

CiteScore

4.20

自引率

4.30%

发文量

330

审稿时长

3-8 weeks

期刊介绍： IN VIVO is an international peer-reviewed journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of physiology, pathology and disease management. The topics of IN VIVO include: 1. Experimental development and application of new diagnostic and therapeutic procedures; 2. Pharmacological and toxicological evaluation of new drugs, drug combinations and drug delivery systems; 3. Clinical trials; 4. Development and characterization of models of biomedical research; 5. Cancer diagnosis and treatment; 6. Immunotherapy and vaccines; 7. Radiotherapy, Imaging; 8. Tissue engineering, Regenerative medicine; 9. Carcinogenesis.